The NLRP3 inflammasome has emerged as a promising therapeutic target in Parkinson's disease (PD). Multiple preclinical and early clinical studies have investigated NLRP3 inhibitors for their potential to slow or halt disease progression by modulating neuroinflammation, a key pathological feature of PD.
In Parkinson's disease, the NLRP3 inflammasome is activated by multiple pathological stimuli:
NT-0796 is a brain-penetrant NLRP3 inhibitor prodrug that has completed Phase 1 clinical testing. A 2025 study demonstrated anti-inflammatory effects in PD subjects, showing modulation of peripheral inflammatory markers [1].
Status: Phase 1 completed, planning Phase 2
Dapansutrile is an orally bioavailable NLRP3 inhibitor that has been studied in multiple inflammatory conditions. Research published in 2023 showed that pharmacological inhibition of NLRP3 reduces α-synuclein levels and protects dopaminergic neurons in preclinical PD models [2].
Status: Preclinical/Phase 1 for CNS indications
MCC950 is a potent and selective NLRP3 inhibitor that blocks ATPase activity [3]. While it showed excellent preclinical efficacy, development was discontinued due to hepatotoxicity in long-term toxicology studies. It remains a valuable research tool.
Status: Discontinued for clinical development (research use only)
Multiple studies have demonstrated that NLRP3 inhibition provides neuroprotective benefits in PD models:
While no large Phase 2/3 trials have completed as of 2026, several early-phase studies are ongoing or recently completed:
Lampropoulou A, et al. Anti-Neuroinflammatory and Anti-Inflammatory Effects of the NLRP3 Inhibitor NT-0796 in Subjects with Parkinson's Disease. Mov Disord. 2025. ↩︎
Angeli A, et al. Pharmacologic inhibition of NLRP3 reduces the levels of alpha-synuclein and protects dopaminergic neurons in a model of Parkinson's disease. NPJ Parkinsons Dis. 2023. ↩︎
Coll RC, Robertson AA, Chae JJ, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015. ↩︎